Abstract
Abstract Breast cancer cells have long been inhibited by polypyridine Ru(II) complexes, which are excellent antitumor agents. Due to their multi-targeting properties, this class of ruthenium complexes has received increasing attention as anticancer drug candidates approach to various cellular targets. The aim of this review is to give information about the ligands that were carefully chosen for ruthenium complexes. There has been a great deal of interest in using ruthenium-based complexes to treat breast cancer. Several species have shown potential as treatment candidates. However, further research is needed to determine how these agents affect the metastatic potential of breast cancer cells. The mechanism of action of Ru-based anticancer candidates NAMI-A and KP1019 during phase I clinical trials has been discussed. This article explains hormone-positive breast cancer and triple-negative breast-cancer treatment by using Ru complexes. Although platinum (Pt-based) anticancer medication is widely used in cancer treatment, a minor improvement has been seen and that is Platinum replaced with Ruthenium for its anticancer properties. We have also highlighted the best effective ruthenium-based complexes in treating T.N.B.C. (triple-negative breast cancer) here in this collection.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
